Stocktoria
Evommune, Inc. EVMN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2025-11-06
Evommune, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 |
|---|---|---|
| Operating margin | -623.6% | -1000.2% |
| Net margin | -529.8% | -954.4% |
| FCF margin | -589.8% | -832.6% |
| Return on assets | -30.6% | -87.8% |
| Return on equity | -33.5% | 46.3% |
| Current ratio | 8.57 | 2.64 |
| Revenue growth | 85.7% | — |
Source: SEC EDGAR filings · CIK 0002044725 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.